Introduction {#Sec1}
============

Deep brain stimulation (DBS) provides symptomatic motor benefit for patients with advanced Parkinson's disease (PD) \[[@CR1]--[@CR4]\]. The benefit of symptom control through DBS surpasses that of optimal medical treatment in patients with motor fluctuations and dyskinesias, and it is a relatively safe treatment option for motor complications of idiopathic PD \[[@CR1]--[@CR5]\]. DBS is often performed in relatively early-onset PD, a population in which it has been estimated that at least 5--10% of cases are not sporadic, but may carry genetic mutations \[[@CR6], [@CR7]\]. Genetic cases often are phenotypically different compared to sporadic patients, and this factor may influence clinical outcome \[[@CR6], [@CR8]\].

Though DBS has demonstrated efficacy, randomized studies have been performed in PD patients without genetic characterization raising questions of suitability of various monogenic forms and their relevance in DBS outcome. It is known that medication effects may vary between different mutations. For example, patients with *PRKN* mutations generally are particularly prone to levodopa-induced dyskinesias, whereas patients with *LRRK2* mutations tend to show a normal sustained benefit for levodopa \[[@CR8]--[@CR11]\]. The effects of other antiparkinsonian drugs, such as rasagiline, may also be modulated by the genotype \[[@CR12]\]. Given the variability in medication effects, it is conceivable that there are also differences in the treatment response to DBS in advanced monogenic PD. There are several case reports and small case series of DBS outcomes in patients with genetic PD, but due to a lack of information synthesis, we performed a systematic review on the effects of DBS in genetic PD.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed \[[@CR13]\]. We performed a PubMed search from inception to June 26, 2018 with keywords "deep brain stimulation or DBS", "Parkinson's or Parkinson or Parkinsonism" and "genetic or gene or GBA or PRKN or PARKIN or LRRK2 or SNCA or PINK1 or VPS35 or DJ-1 or UCHL1 or GIGYF2 or HTRA2 or TMEM230 or CHCHD2 or RIC3 or ATP13A2 or PLA2G6 or FBX07 or SYNJ1 or VPS13C or DNAJC6". All original English language articles concerning genetic PD patients treated with DBS were included. Animal studies and review articles were excluded.

The initial search identified 220 articles, and we included an additional 16 relevant studies found in the manual search of reference lists (Fig. [1](#Fig1){ref-type="fig"}). All abstracts of these studies were screened, and 184 studies were excluded in the first round (no monogenic PD patients or not treated with DBS *n* = 64, review or commentary article *n* = 92, animal study *n* = 28). The remaining 52 studies were assessed fully for eligibility and six more studies were excluded in the second round (genetic test negative *n* = 2, no genetic testing *n* = 1, review or commentary article *n* = 3). Finally, 46 studies of these 236 studies met all selection criteria and were included in the systematic review (Table [1](#Tab1){ref-type="table"}). A summary of the included studies is presented in Table [2](#Tab2){ref-type="table"}. The included studies reported 221 genetic PD patients who were treated with DBS. However, two studies reported partially the same patients \[[@CR14], [@CR15]\].

Fig. 1Flow chart of study inclusion and exclusion

Table 1The data extracted from the included studiesStudy*N*GeneMutation^a^AAO^a^AAD^a^Target^a^LPPRE-UPDRS III^a^POST-UPDRS III^a^%^b^FUNOSOutcomeHealy et al. \[[@CR9]\]18*LRRK2*p.G2019SNANA^A^STN^c^NANANANANA4Good or excellent (*n* = 8), moderate (*n* = 2), poor (*n* = 2) and NA (*n* = 6)Sayad et al. \[[@CR16]\]15*LRRK2*p.G2019S40.1 ± 9.4NASTN bilat.+55.8 ± 16.4 M−, 25.0 ± 13.2 M+ (NC: 51.7 ± 14.4 M−)27.3 ± 20.6 M−S+, 19.7 ± 18.8 M+S+ (NC: 38.5 ± 16.6 M−S+)51.1 (NC: 25.5)210Favourable and better outcome compared to patients without mutationGreenbaum et al. \[[@CR17]\]13*LRRK2*p.G2019S49.5 ± 6.861.1 ± 6.6STN bilat.+42.5 ± 11.8 M−, 19.5 ± 13 M+ (NC: 43.4 ± 12.3 M−)Short FU 28.5 ± 13.1 M−S+, 17.4 ± 12.9 M+S+ Long FU 30.5 ± 12.8 M−S+, 21.2 ± 9.2 M+S+ (NC: Short FU 27.2 ± 14.1 M−S+, Long FU 33.9 ± 16.1 M−S+)Short FU 32.8 ± 31.1Long FU 28.5 ± 32.9 (NC: Short FU 35.6 ± 25.3, Long FU 17 ± 37.1)0.5--1 (*n* = 13), 3 (*n* = 11)10Favourable and comparable to patients without mutations. One patient reported new/worse psychiatric symptoms at 3-year follow-upSchüpbach et al. \[[@CR18]\]9*LRRK2*p.G2019S (*n* = 7)p.G2019S + het. *PRKN* mutation (*n* = 1), p.T2031S (*n* = 1)33--4838--65STN bilat.NA41.4 ± 12.4 M−, 8.2 ± 4.6 M+ (NC: 43.4 ± 17.0 M−)47.7 ± 13.1 M−S−, 17.8 ± 9.6 M−S+, 11.8 ± 4.5 M+S−, 6.2 ± 3.9 M+S+ (NC: 15.7 ± 9.0)50 ± 36 (NC: 64)9--10 (Long-term FU for two patients)10Favourable and comparable to patients without mutations, but cognitive, behavioral and psychotic problems in the patient with p.T2031S mutation after 5 yearsPal et al. \[[@CR19]\]5*LRRK2*NA47.5 ± 11.0 (*n* = 4)60.8 ± 9.0 (*n* = 4)NANANA30.8 ± 11.7 M+S+ (*n* = 4)NA3.5 ± 2.4 (*n* = 4)6The outcome is not reported. Clinical data before DBS is not available, but UPDRS III score was higher in LRRK2 -patients compared to patients without mutations at follow-upAngeli et al. \[[@CR15]\]5*LRRK2*p.G2019S (*n* = 4), p.G2019S + *GBA*-E326K (*n* = 1)35--55NA^B^STN^c^NA65.4 ± 14.9 M−, 10.8 ± 5.1 M+ (NC: 47.6 ± 14.8 M−)69.2 ± 12.4 M−S−, 30.6 ± 16.1 M−S+ (24.6 ± 11.3 M−S+)53 (NC: 48)1--59Favourable and comparable to patients without mutations. No reported cognitive problemsGómez-Esteban et al. \[[@CR20]\]4*LRRK2*p.R1441G29--5541--65STN bilat.+48.5 ± 18.5 M−, 18.0 ± 7.4 M+ (NC: 42.5 ± 10.6 M−)39.7 ± 17.7 M−S+, 16.0 ±/--7.7 M+S+ (NC: 26.1 ± 8.4 M−S+)18 (NC: 39)0.510Poorer response compared to patients without mutationJohansen et al. \[[@CR21]\]3*LRRK2*p.G2019S43--5750--69STN bilat.+NA for individual genes (NC: 35.7 ± 6.7 M−)NA for individual genes (NC: 19.7 ± 5.5 M−S+)NA (NC: 44.8)59Favourable and comparable to patients without mutationsLesage et al. \[[@CR22]\]3*LRRK2*p.G2019S (*n* = 2), p.T2031S (*n* = 1)34--4541--66STN^c^NA14 M+ (*n* = 1), NA (*n* = 2)27 M−S+ (*n* = 1), 17 M−S+ and 32 M−S− (*n* = 1)NA7 (Long-term FU for one patient)9Favourable to motor symptoms, but depression and psychosis in the patient with p.T2031S mutationGaig et al. \[[@CR23]\]3*LRRK2*p.G2019S33--62NASTN bilat.NANANANANA5Favourable to motor symptomsGoldwurm et al. \[[@CR24]\]3*LRRK2*p.G2019SNANANANANANANANA2NAHatano et al. \[[@CR25]\]1*LRRK2*p.R1441G and p.G2385R2839STN bilat.+NANANA27Poor motor response with severe psychiatric problems at 1 year after operationStefani et al. \[[@CR26]\]1*LRRK2*Het. p.G2019S4956STN bilat.+27 M−, 12 M+25 M−S−, 8 M−S+, 5 M+S+70.40.258Favourable outcomePuschmann et al. \[[@CR27]\]1*LRRK2*p.N1437H (c.4309A \> C)5069STN bilat.+NA65 M−S+NA0.58Poor motor outcome. Patient had also severe depression and suicidality and she finally committed suicide 6.5 months after DBS implantationPerju-Dumprava et al. \[[@CR28]\]1*LRRK2*p.Y1699C4348STN bilat.NA54 M−, 32 M+26 M−S+, 15 M+S+52 M−, 53 M+2.510Favourable outcome. No changes in neuropsychological test parameters 6 months postoperativelyBreit et al. \[[@CR29]\]1*LRRK2*p.R793M4260STN bilat.NANANA64 (1 year), 56 (8 year)88Favourable outcomeAasly et al. \[[@CR30]\]1*LRRK2*p.Asn1437HisNANASTN^c^NANANANANA4Favourable outcomeLohmann et al. \[[@CR31]\]14*PRKN*One mutation: ex6hetdupl, ex6hetdel, Arg256Cyshet \[*n* = 2\], Ala398Thrhet, ex7hetdupl, and exhet3del; Hom. or compound het.: ex5hetdel---c.255delAhet, ex3hetdel---prom-ex1hetdel, ex2-4hetdupl---ex3hetdel, Cys289Glyhom, ex5hetdel---Cys441Arghet, ex2hetdel---ex3hetdel and ex4-7hetdel---IVS7-1GC14--5232--67STN bilat.NAOne mutation 54.3 ± 13.9 M−, 11.6 ± 12.7 M+Two mutations 55.4 ± 17.3 M−, 14.5 ± 10 M+ (NC: 51.9 ± 18.3 M−)One mutation 38.4 ± 16.8 M−S−12.7 ± 11.2 M+S−, 17.8 ± 11.2M−S+, 10.8 ± 10.1M + S+Two mutations 47.7 ± 12.8 M−S−, 17 ± 10.9M−S+, 14.5 ± 12.5 M−S+, 9.3 ± 8.6 M+S+ (NC: 17.9 ± 15.1 M−S+)One mutation 69 ± 15Two mutations 77 ± 14 (MC: 65.5)1--2 except 3 years for one patient with two PRKN mutations10Motor response was favourable and comparable to patients without mutations, but more cognitive problems in homozygous and compound heterozygous patients compared to patients without mutationsMoro et al. \[[@CR32]\]11*PRKN*One mutation: delEx6, duplEx5, 867C \> T, 1306G \> C, delEx5-12; Hom. or compound het.: 202delA \[*n* = 2\], delEx3-4, delEx3 + 1142-3delGA, delEx2-5 + duplEx8, delEx7-915--4031--66STN bilat.NA35--66 (MV = 49.5)NAShort FU 36Long FU 42 (NC: Short FU 56, Long FU 44)3--69Favourable and comparable to patients without mutations in long-term follow-upPal et al. \[[@CR19]\]10*PRKN*NA30.6 ± 9.147.0 ± 11.5NANANA33.8 ± 20.5 M+S+ (*n* = 6)NA4.0 ± 4.26The outcome is not reported. Clinical data before DBS is not available but UPDRS III score was higher in PRKN -patients compared to patients without mutations at follow-upAngeli et al. \[[@CR15]\]5*PRKN*Hom.: c.101_102delAG, c.1289G \> A p.G430D and c.823C \> T, p.Arg275Trp, c.337_376del and c.465--466del, Hom. deletion of exon 3 and 4, c.823C \> T; p.Arg275Trp and het. duplication of exon 67--36NA^B^GPi (*n* = 3), STN^c^ (*n* = 2)NAAll 57.0 ± 11.2 M−, 21.0 ± 6.4 M+GPi 53.3 ± 13.9 M−STN 62.5 ± 3.5 M−(NC: STN: 47.6 ± 14.8M−GPi: 40.5 ± 13.4 M−)GPi 43.3 ± 16.4 M−S−42.0 ± 19.0M−S+  27.3 ± 17.6 M+S+STN 84.0 ± 22.6M-S−43.0 ± 0.0 M-S+23.5 ± 6.4 M+S+ (NC: STN: 24.6 ± 11.3 M-S+, GPi: 51.0 ± 7.1 M-S+)GPi 21STN 31 (NC: STN: 48, GPi: − 28)1--59Good to motor symptoms without cognitive problems. The percentage improvement in the UPDRS III score was better with STN-DBS than with GPi-DBSRomito et al. \[[@CR11]\]5*PRKN*G828A and Dupl ex1, DelAG 202-203, C1101T, G535A, Dupl ex127--4542--63STN bilat.+57.3 ± 9.3 M−22.8 ± 7.3 M+ (NC: 59.7 ± 11.3 M−)25.2 ± 10.0 M−S+21.8 ± 7.5 M+S+(NC: 29.0 ± 12.3 M−S+)56 (NC: 51.4)1--310Favourable and comparable to patients without mutationsJohansen et al. \[[@CR21]\]4*PRKN*Het. c.delEx3, Het. p.R275W, Het. c.duplEx7, Hom. c.delEx5 (GPi)35--4650--59STN bilat. (*n* = 3), GPi unilat. (*n* = 1)+NA for individual genes (NC: 35.7 ± 6.7 M−)NA for individual genes (NC: 19.7 ± 5.5 M−S+)NA (NC: 44.8)5--79Favourable and comparable to patients without mutationsKim et al. \[[@CR33]\]3*PRKN*NA21.7 ± 8.549.7 ± 16.2STN bilat.NA49.8 ± 24.5 M−, 18.3 ± 7.8 M+ (NC: 38.3 ± 10.6 M−)24.7 ± 14.0 M−S+, 22.2 ± 14.9 M+S+ (NC: 17.2 ± 5.5 M−S+)37.1 ± 45.4 (NC: 54.6 ± 13.9)2--510Favourable and comparable to patients without mutationsHassin-Baer et al. \[[@CR34]\]3*PRKN*Hom. 202 A deletion15--2831--54STN^c^NA27--64 M−, 20--48 M+NANANA7Modest outcome with improvement in appendicular symptoms, but no change in axial featuresSayad et al. \[[@CR16]\]2*PRKN*Het. c. 458C \> G48NASTN bilat.+46 M−, 28 M+51 M−S+, 30 M+S+− 10.1210Poor responseHet. c. 1204C \> T48+49 M−, 32 M+ (NC: 51.7 ± 14.4 M−)51 M−S+, 47 M+S+ (NC: 38.5 ± 16.6 M−S+)− 4.1 (NC: 25.5)Thompson et al. \[[@CR35]\]2*PRKN*Hom., specific mutation NA26 (Gpi), 30 (STN)NASTN bilat. (*n* = 1), GPi bilat. (*n* = 1)NAGPi 57 M−, 50 M+STN 47 M−, 21 M+NANA3 (STN), 8 (GPi)6Favourable outcomeGenç et al. \[[@CR36]\]1*PRKN*Het. c89G \> A and large het. deletion10NASTN bilat.+48 M−, 7 M+7 M−S+, 4 M+S+85.4NA6Favourable to motor symptomsMoll et al. \[[@CR37]\]1*PRKN*Compound het. *PRKN* mutation (delExon1 + c.924C \> T)3545STN bilat.+30 M−5 M+NANANA7Favourable to motor symptomsNakahara et al. \[[@CR38]\]1*PRKN* + *PINK1*Hom. parkin mutation (p.T175PfsX2) + het. PINK1 mutation (p.R58-V59insGR)1560STN bilat.+86 M−, 25 M+33 M−S+, 21 M+S+620.79Favourable outcomeLefaucheur et al. \[[@CR39]\]1*PRKN*Compound het. mutations of the *PRKN* gene, \[c.101_102delAG (p.Gln34ArgfsX5) + c.155delA (p.Asn52MetfsX29)\]2569STN^c^NANANA550.58Favourable to motor symptoms without cognitive problemsWickremaratchi et al. \[[@CR40]\]1*PRKN*Compound het. exon 2/exon 2 1 3 deletion in the *PRKN*846Zona incerta bilat.NA68 M−, 22 M+NA M−S+ 24 M+S+NA M−, 64.7 M+0.59Favourable outcomeLesage et al. \[[@CR41]\]1*PRKN*Compound het. of the *PRKN* c.1-?\_7+?del and c.172-?\_412+?del mutations839STN bilat.NA46 M−, 15.5 M+NANANA6Favourable outcomeCapecci et al. \[[@CR42]\]1*PRKN*Hom. deletion in exon 322NASTN bilat.+45 M−, 5 M+7 M−S+, 3 M+S+84.418Favourable outcomeKhan et al. \[[@CR43]\]1*PRKN*Exon 9 1101C--\>T (Arg334Cys), exon 7 939G--\>A (Asp230Asn)3035STN bilat.NANANANANA6Favourable outcomeLythe et al. \[[@CR14]\]17^d^*GBA*Het. mutation carriers (*n* = 15), hom. mutation carrier (*n* = 1), compound het. (*n* = 1). Two patients also carried a mutation in another PD-associated gene; *PARKIN* or *LRRK2*41.4 ± 5.853.5 ± 4.5STN^c^ (*n* = 15), GPi (*n* = 2)NA52.4 ± 13.0 M−, 18.4 ± 14.9 M+ (NC: 40.5 ± 12.0 M−)NA M−S+, 50.0 ± 17.1 M+S+ (*n* = 9) (NC: NA M−S+, 38.9 ± 14.0 M+S+)4.6 M+S+ (*n* = 9) (NC: 4.0 M+S+)7.5 (*n* = 9)9Follow-up data available for 9 patients. Poorer outcome compared to patients without mutations. GBA mutation carriers had faster rate of cognitive decline, reported significantly worse quality of life and exhibited a greater burden of non-motor symptoms compared to patients without mutations.During follow-up 3 GBA + patients were deceased, 2 were unable to complete follow-up due to severe PD-related disability, 2 could not be contacted and 1 DBS hardware was removedAngeli et al. \[[@CR15]\]16*GBA*R463C/R463C, L444P/E326K, N370S, D409H, recNcil, R463C, N188S, R275Q, IVS2 + 1 G \> A, L444P, E326K/E326K, E326K (*n* = 3), E326K and *LRRK2* p.G2019S, T369M and *PRKN* c.1310C \> T34--58NA^B^STN^c^ (*n* = 13), GPi (*n* = 2), VIM (*n* = 1)NAAll 51.3 ± 14.0 M−, 18.0 ± 15.4M+GPi 64.5 ± 21.9M−STN 50.5 ± 12.4 M−VIM 35 M− (NC: STN: 47.6 ± 14.8 M−GPi: 40.5 ± 13.4 M−)GPi 66.5 ± 19.1 M−S−, 50.0 ± 19.8 M−S+, 41.0 ± 15.6 M+S+STN 56.1 ± 18.8 M−S−, 28 ± 11.4 M−S+, 15.9 ± 10.4 M+S+VIM 35 M−S−, 20 M−S+, 8 M+S+ (NC: STN: 24.6 ± 11.3 M−S+ GPi: 51.0 ± 7.1 M−S+)GPi 22STN 40VIM 43 (NC: STN: 48, GPi: − 28)1--59Favourable motor response, but faster rate of cognitive decline compared to patients without mutations. The percentage improvement in the UPDRS III score "OFF- medication" was better with bilateral STN-DBS and VIM-DBS than with GPi-DBSPal et al. \[[@CR19]\]12*GBA*p.N370S (*n* = 8), p.L444P (*n* = 3). 1 patient carried both GBA and LRRK2 mutations and was excluded41.6 ± 5.3 (*n* = 11)53.9 ± 2.6(*n* = 9)NANANA27.4 ± 14.5 M+S+ (*n* = 11)NA1.6 ± 3.0 (*n* = 9)6The outcome is not reported. Clinical data before DBS is not available, but UPDRS-III score was little higher in GBA -patients compared to patients without mutations at follow-upWeiss et al. \[[@CR44]\]3*GBA*p.N370S (*n* = 1) and p.L444P (*n* = 2)47--5465--69STN^c^NA26 and 53 M−, 14 and 19 M+, NA (*n* = 1) (NC: 31--63 M−)56--71M−S−, 21--45M−S+, 32--48 M+S−, 20--45 M+S+ (NC: 21--42 M−S+)30--75 (NC: 22--54)6--1011Favourable outcome, but substantial increase of axial motor impairment in the long-term with declining therapeutic response in *GBA* carriers. *GBA* carriers developed also a significant cognitive impairmentLesage et al. \[[@CR45]\]2*GBA*Hom. p.N370S52NASTN bilat.NANANANANA5Favourable outcomec.1263del + RecTL21242Some clinical benefit 2 years after DBS, but problems with postural instabilityMartikainen et al. \[[@CR46]\]1*SNCA*Het. c.158C \> A (p.A53E)4246STN bilat.NA31 M−, 8 M+NANA3.59Favourable motor outcome in the short-term but poor in the long-term follow-up.Response for motor fluctuations remained satisfactory but the cognitive and mental state of the patient deteriorated to a state of practical immobilityPerandones et al. \[[@CR47]\]1*SNCASNCA* duplication1826GPi bilat.+NANANA0.16Favourable and comparable to patients without mutationsShimo et al. \[[@CR48]\]1*SNCASNCA* duplication3541STN bilat.+27 M−, 10 M+13 M−S+51.949Favourable motor outcome without cognitive or psychiatric problemsAntonini et al. \[[@CR49]\]1*SNCASNCA* duplication at 4q22.14146STN bilat.+28 M−, 10 M+16 M−S+, 10 M+S+42.929Favourable outcome in short-term follow-up but patient developed visual hallucinations and cognitive deterioration and died two years after operation due to metastatic breast cancerAhn et al. \[[@CR50]\]1*SNCASNCA* duplication4046STN bilat.NA32 M−, 6 M+NANANA6Excellent motor response but later patient's dementia worsened, requiring assistance in daily activitiesFleury et al. \[[@CR51]\]2*VPS35*p.D620N4960STN bilat.NA58 M−, 17 M+32 M−S−, 18 M−S+, 18 M+S−, 15 M+S+76 (1 year)69(8 years)88Favourable outcome455528 M−, 15 M+NA36 (1 year)1Tremor, akinesia and rigidity improved markedly but patient's walking difficulties worsened with an increased frequency of freezing episodes and falls after surgery (problems disappeared after levodopa intake with the STN-DBS switched on)Chen et al. \[[@CR52]\]1*VPS35*p.D620N4255STN bilat.+42 M−, 15 M+35 M−S−, 22 M−S+, 15 M+S−, 13 M+S+3759Favourable outcomeKumar et al. \[[@CR53]\]1*VPS35*p.D620NNANANANANANANANA3Little benefit to motor symptoms, but patient developed significant dysarthriaSheerin et al. \[[@CR54]\]1*VPS35*p.D620N47NANANANANANANA5Favourable outcome. No reported cognitive problemsBorellini et al. \[[@CR55]\]1*PINK1*Hom. L347P3049GPiNA44 M−32 M + S+270.17Moderate outcomeNakahara et al. \[[@CR38]\]1*PRKN* + *PINK1*Hom. parkin mutation (p.T175PfsX2) + het. PINK1 mutation (p.R58-V59insGR)1560STN bilat.+86 M−, 25 M+33 M−S+, 21 M + S+620.79Favourable outcomeJohansen et al. \[[@CR21]\]1*PINK1*Het. p.G411S5059STN bilat.+NA for individual genes (NC: 35.7 ± 6.7 M−)NA for individual genes (NC: 19.7 ± 5.5 M−S+)NA (NC: 44.8)59Favourable and comparable to patients without mutationsMoro et al. \[[@CR32]\]1*PINK1*Hom. c.509T \> G (p.V170G)3161STN bilat.NA35.5 M−NAShort FU 46.5Long FU 43.7 (NC: Short FU 56, Long FU 44)3--69Favourable and comparable to patients without mutationsValente et al. \[[@CR56]\]1*PINK1*NANANASTN bilat.NANANANANA3Motor outcome was not properly reported but patient developed imbalance, gait impairment, dysarthria, and behavioral changes at the age of 54 years. Mental deterioration was documented a few years laterDufournet et al. \[[@CR57]\]322q11.2 Del. Syndrome34--38^e^NASTN^c^ (*n* = 1)GPi (*n* = 2)NANANA30--70NA7Favourable and comparable to patients with idiopathic PD*AAO* age at disease onset (years), *AAD* age at DBS operation (years), *LP* specific lead position (reported or not), *%* the percentage improvement of the UPDRS III score after DBS^b^, *FU* follow-up after surgery (years), *NA* not available, *M−/+* medication OFF/ON, *S−/+* stimulation OFF/ON, *MV* mean value, *NC* mutation non-carriers^A^The mean time from PD onset to surgery was 11.4 years (SD 6.2), ^B^mean duration of PD (years) at DBS assessment: PRKN = 25.2 ± 12.8, GBA = 11.2 ± 5.0, LRRK2 = 12.1 ± 1.8^a^Parameters are reported in the table as in the original articles^b^If the percentage improvement was not reported directly in the original article but UPDRS-III scores were available, we calculated the percentage improvement from the change of UPDRS-III score in the preoperative M− condition compared to the postoperative M−S+ condition (((Pre-op. UPDRS-III M−) − (Post.op. UPDRS-III M−S+))/(Pre-op. UPDRS-III M−) × 100)^c^The study did not specify whether the implantation was uni- or bilateral^d^Some patients were reported previously by Angeli et al. \[[@CR15]\]^e^Age at PD diagnosis

Table 2Summary of key findings according to the mutated geneGeneStudies (*n*)Patients (*n*)TargetOutcome*LRRK2*1787^a^STN: *n* = 79 (90.8%)NA: *n* = 8 (9.2%)Mostly favourable motor outcome. Four studies with eight patients (9.2%) reported poor motor outcomes and one study reported moderate outcomes for two patients. Both patients with the *LRRK2* p.T2031S (c.6091A \> T) mutation (*n* = 2) developed neuropsychiatric problems 5--7 years after implantation. The outcome appears poor in patients with *LRRK2* p.R1441G (c.4321C \> G) mutations (*n* = 5), whereas it appears excellent in patients with *LRRK2* p.G2019S (c.6055G \> A) mutations*PRKN*1867^b^STN: *n* = 51 (76.1%)GPi: *n* = 5 (7.5%)Zona incerta: *n* = 1 (1.5%)NA: *n* = 10 (14.9%)Fifty-one patients (76.1%) had favourable long-term motor outcomes. Four patients (6.0%) were reported to have modest outcome in two different studies and one study with two patients (3.0%) reported poor benefit*GBA*550^c^STN: *n* = 33 (66.0%)GPi: *n* = 4 (8.0%)VIM: *n* = 1 (2.0%)NA: *n* = 12 (24.0%)Eighteen patients were reported to have favourable, three patients moderate and 9 patients poor long-term motor outcomes. One study reported better outcomes with STN-DBS and VIM-DBS than with GPi-DBS. *GBA* mutation carriers developed cognitive impairment faster than patients without mutations*SNCA*55STN: *n* = 4 (80.0%)GPi: *n* = 1 (20.0%)Favourable motor outcome but three of five patients developed cognitive or neuropsychiatric problems a few years after implantation*VPS35*45STN: *n* = 3 (60.0%)NA: *n* = 2 (40.0%)Favourable motor outcome in four cases and minor motor benefit complicated by dysarthria in one case*PINK1*55^b^STN: *n* = 4 (80.0%)GPi: *n* = 1 (20.0%)Favourable motor outcome in three cases and moderate in one case*22q11.2.Del. Syndrome*13STN: *n* = 1 (33.3%)GPi: *n* = 2 (66.6%)Favourable motor outcome*STN* subthalamic nucleus, *GPi* globus pallidus interna, *VIM* ventral intermediate nucleus, *NA* not available^a^One patient had also PRKN mutation and one had GBA mutation^b^One patient had both PRKN and PINK1 mutations^c^Two studies reported partially same patients, but it was not possible to separate individual patients that were reported twice. One patient had also LRRK2 mutation and one had PRKN mutation

Specific aims {#Sec4}
-------------

This review of evidence aimed to systematically investigate DBS outcome in monogenic PD compared to the general PD population. The primary aim was to evaluate the motor benefit of the DBS operation in each monogenic PD type. An additional aim was to evaluate effects on non-motor symptoms, including possible cognitive and neuropsychiatric symptoms.

Selection criteria {#Sec5}
------------------

Search terms and the PubMed search were planned by two authors (T.K. and V.K.). All titles and abstracts were reviewed by one investigator (T.K.). Studies were excluded if the title and/or abstract were not suitable for the aim of the review. Full texts were obtained for appropriate studies or if the relevance of an article was uncertain. The inclusion criteria for the selected studies were as follows: (1) a human study, (2) genetic PD patients treated with DBS, and (3) English language. The data extracted from each study were study year, first author's family name, number of patients, mutated gene, specific mutation, patient age at disease onset and DBS implantation, target nucleus of DBS, more specific lead positioning, pre- and postoperative UPDRS-III scores, follow-up time and outcome (Table [1](#Tab1){ref-type="table"}). UPDRS-III scores of control cohort\'s (mutation non-carriers, NC) are also reported in Table [1](#Tab1){ref-type="table"} if the information was available. In the outcome evaluation, an improvement of 30% or more in the UPDRS-III motor score was considered to indicate favourable outcome; 20--30%, moderate outcome; and \< 20%, poor/mild outcome \[[@CR58]--[@CR60]\].

Quality control {#Sec6}
---------------

The quality of the included studies was evaluated according to the Newcastle-Ottawa Scale (NOS) \[[@CR61]\]. NOS includes selection, comparability, and exposure or outcome. The scale ranged from 0 to 11 stars, with the highest rating representing the greatest quality. Six months or more was a limit for the adequate follow-up time. Pre- and postoperative evaluation was thought to be accomplished if the outcome was reported properly with percentage improvement of the UPDRS-III score or verbally. A total score of 0--3 was considered to indicate to poor quality; 4--7, moderate quality; and 8--11, good quality. The NOS total score is presented in Table [1](#Tab1){ref-type="table"} and the scale is presented more accurately in Supplementary Table 1. A summary of the assessed quality of the studies is presented in Supplementary Table 2.

Results {#Sec7}
=======

A summary of the primary results is presented in Table [2](#Tab2){ref-type="table"}. Altogether, 46 studies and 221 monogenic PD patients treated with DBS were included in the systematic review (Table [1](#Tab1){ref-type="table"}).

LRRK2 {#Sec8}
-----

Seventeen studies \[[@CR9], [@CR15]--[@CR30]\] reported 87 patients (target: subthalamic nucleus (STN) *n* = 79, not available (NA) *n* = 8). The outcome was reported in 73 patients (83.9% of patients); with percentage improvement of the UPDRS-III score in 49 patients and verbally in 24 patients. The motor outcome was mostly favourable in patients with *LRRK2* mutation. Only five studies with ten patients reported poor/mild/moderate outcomes. Both patients with the p.T2031S (c.6091A \> T) mutation (*n* = 2) developed neuropsychiatric problems 5--7 years after implantation. The outcome appeared poor in patients with p.R1441G (c.4321C \> G) mutations whereas it appeared excellent in patients with p.G2019S (c.6055G \> A) mutations.

PRKN {#Sec9}
----

Eighteen studies \[[@CR11], [@CR15], [@CR16], [@CR19], [@CR21], [@CR31]--[@CR43]\] reported 67 patients (STN *n* = 51, globus pallidus interna (GPi) *n* = 5, zona incerta *n* = 1, NA *n* = 10). The outcome was reported in 57 patients (85.1%); UPDRS-III percentage improvement was reported in 45 patients and the outcome was described verbally in 12 patients. Fifty-one patients (76.1%) had favourable long-term motor outcomes. Six patients in three different studies were reported to have modest or poor outcomes.

GBA {#Sec10}
---

Five studies \[[@CR14], [@CR15], [@CR19], [@CR44], [@CR45]\] reported 50 patients (STN *n* = 33, GPi *n* = 4, ventral intermediate nucleus (VIM) *n* = 1, NA *n* = 12). Samples partially consisted of same patients in two studies \[[@CR14], [@CR15]\]. The outcome was reported in 30 patients (60.0%); UPDRS-III percentage improvement in 28 patients and the outcome was described verbally in 2 patients. Eighteen patients were reported to have favourable, three patients moderate and nine patients poor long-term motor outcomes. One study reported better outcomes with STN-DBS and VIM-DBS than with GPi-DBS \[[@CR15]\]. GBA mutation carriers developed cognitive impairment faster than patients without mutations.

SNCA {#Sec11}
----

Five patients were reported in five case reports \[[@CR46]--[@CR50]\] (STN *n* = 4, GPi *n* = 1). The motor outcome was favourable for all patients in the short-term but 3/5 patients developed cognitive and/or neuropsychiatric problems a few years after implantation. The percentage change in the UPDRS-III score was documented in two patients.

VPS35 {#Sec12}
-----

Four studies \[[@CR51]--[@CR54]\] reported five patients (STN *n* = 3, NA *n* = 2). Favourable motor outcome was reported in four cases and minor motor benefit complicated by dysarthria in one case. The percentage change in the UPDRS-III score was reported in three patients.

PINK1 {#Sec13}
-----

Five case reports \[[@CR21], [@CR32], [@CR38], [@CR55], [@CR56]\] including one patient in each report (STN *n* = 4, GPi *n* = 1) were reported. Favourable motor outcome was observed in three patients and moderate outcome in one case. One patient developed imbalance, gait impairment, dysarthria, and behavioral changes after operation and mental deterioration was documented a few years later.

Exclusion of poorer quality studies {#Sec013}
-----------------------------------

Unfortunately, many studies (Table [1](#Tab1){ref-type="table"}) lacked important information as shown in the Supplementary Table 1. Poorer quality studies have tendency for bias; therefore, in the Supplementary Table 3, data are presented after exclusion of poorer quality studies such as studies lacking the information about DBS target, pre- and postoperative evaluation, adequate follow-up time or outcome information. Furthermore, as Lythe et al. \[[@CR14]\] and Angeli et al. \[[@CR15]\] reported partly the same patients, we tested the conclusions also when the smaller study was excluded. Nevertheless, after the exclusion of these studies, the results remained essentially the same (Supplementary Table 4).

Discussion {#Sec14}
==========

We report the following key findings: (1) DBS outcome appears excellent in patients with *LRRK2* p.G2019S (c.6055G \> A) mutations, good in patients with *PRKN* mutations and poor in patients with *LRRK2* p.R1441G (c.4321C \> G) mutations, (2) the overall benefit of DBS in *SNCA, GBA* and *LRRK2* p.T2031S (c.6091A \> T) mutations may be decreased due to rapid progression of cognitive and neuropsychiatric symptoms, and (3) in other mutations, the motor outcome in DBS-treated genetic PD patients appears generally comparable to that of sporadic PD patients.

A recent smaller review of 30 studies described the effects of DBS mainly in patients with *LRRK2, PRKN* and *GBA* mutations \[[@CR62]\]. In the present PRISMA-compliant systematic review of 46 studies and 221 patients, the most comprehensive data were available for patients with *LRRK2* and *PRKN* mutations. The combined evidence suggests that patients with *LRRK2* mutations generally have a good response to DBS, and patients with the most common *LRRK2* mutation, the p.G2019S mutation \[[@CR7]\], may even have better outcome than the general PD population. However, the reported *LRRK2* cases of p.R114G, p.T2031S and p.N1437H (c.4309A \> C) mutation carriers appeared to have less favourable outcome. This interpretation is limited by the small number of reported DBS-treated cases of rarer *LRRK2* mutations. For the *PRKN* mutations, the literature supports a view that patients with *PRKN* mutations are optimal candidates for DBS.

Apart from the *LRRK2* and *PRKN* genes, the published literature concerning individual monogenic mutations and DBS is less comprehensive and the data are clearly limited with respect to both the number of patients and duration of follow-up. The available data are limited to five DBS-treated patients with *VPS35* mutation, and the patients have shown favourable sustained motor outcome in 4/5 cases. The available literature also suggests that most patients with mutations in *GBA* tend to achieve favourable long-term motor outcome from STN-DBS. Despite good motor outcome, *GBA* mutation carriers may develop cognitive impairment after DBS faster than patients without mutations. *SNCA* patients commonly develop cognitive and neuropsychiatric problems \[[@CR8]\]. The literature supported a good motor outcome after DBS also in patients with SNCA mutations; however, 3/5 patients developed cognitive and neuropsychiatric problems a few years after DBS implantation. Indeed, the non-motor features of genetic PD may be a limiting factor in the overall benefit of DBS in some mutations, such as *SNCA* and *LRRK2* p.T2031S. While the motor benefit from DBS may initially be clear, the rapid non-motor progression may lessen the sum value for the quality of life. A recent study in *SNCA* A53T mutated rodents suggested that DBS may be neuroprotective \[[@CR63]\]. Nonetheless, in human PD patients with *SNCA* mutations, the neuropsychiatric progression appears to be rapid despite DBS. The issue could be the level of damage at the time of implantation, and earlier DBS in these patients might possibly provide different outcomes.

Preoperative response to levodopa is the best single predictor of the postoperative outcome of DBS \[[@CR64]\]. This indicator appears useful also in patients with monogenic mutations and the response was reported in practically all included studies. Another relevant predictor is the localization of DBS electrodes \[[@CR65]\]. Unfortunately, there were studies, which did not report DBS targets and most studies lacked information about lead positioning. As the literature expands in the future, the effect of targets and lead positioning should be investigated in more detail. In most studies, STN was preferred over GPi as the target. Hence it remains ambiguous whether there are any relevant differences of clinical outcome between STN and GPi stimulation in monogenic PD. One study reported also a patient with VIM stimulation which is an unusual target for PD patients because VIM stimulation improves only tremor, not other PD symptoms \[[@CR66], [@CR67]\]. Finally, it is important to note that the genetic status may have a positive as well as a negative influence on outcome of surgery and this issue should be taken into consideration in the interpretation of DBS studies. For example, the EARLYSTIM trial was performed with young-onset PD patients \[[@CR5]\] and there could have been an overrepresentation of PRKN patients in the sample.

In conclusion, monogenic PD patients have variable DBS outcomes depending on the mutated gene. Most patients benefit from STN-DBS, at least in the short-term; however, the current evidence does not support or is questionable for DBS implantation for patients with p.T2031S or p.R114G mutations in the *LRRK2* gene or mutations in the *SNCA* or *GBA* genes. The best outcome from DBS surgery appears to be in patients with *LRRK2* p.G2019S or *PRKN* mutations.
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